Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Equities researchers at Brookline Capital Management lifted their FY2027 EPS estimates for Intellia Therapeutics in a note issued to investors on Thursday, February 27th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings per share of $22.48 for the year, up from their previous forecast of $22.30. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($5.07) per share. Brookline Capital Management also issued estimates for Intellia Therapeutics' FY2028 earnings at $47.65 EPS and FY2029 earnings at $95.29 EPS.
Other equities research analysts have also issued reports about the company. Barclays cut their price objective on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday. Citigroup boosted their price target on Intellia Therapeutics from $12.00 to $14.00 and gave the stock a "neutral" rating in a research report on Friday. StockNews.com upgraded Intellia Therapeutics to a "sell" rating in a report on Friday, November 8th. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $13.00 target price (down previously from $45.00) on shares of Intellia Therapeutics in a research note on Friday. Finally, BMO Capital Markets reduced their target price on shares of Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating for the company in a research report on Friday, January 10th. Two analysts have rated the stock with a sell rating, six have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $42.12.
Read Our Latest Stock Analysis on NTLA
Intellia Therapeutics Stock Performance
Shares of NTLA traded down $0.64 during mid-day trading on Monday, hitting $9.45. 2,998,270 shares of the company were exchanged, compared to its average volume of 3,289,680. The stock has a market cap of $962.47 million, a price-to-earnings ratio of -1.74 and a beta of 1.80. Intellia Therapeutics has a 1-year low of $8.96 and a 1-year high of $33.28. The company has a 50 day moving average of $10.85 and a 200-day moving average of $15.55.
Institutional Investors Weigh In On Intellia Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in NTLA. ARK Investment Management LLC grew its holdings in shares of Intellia Therapeutics by 2.3% during the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock worth $146,174,000 after purchasing an additional 280,946 shares during the period. Vanguard Group Inc. lifted its position in Intellia Therapeutics by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company's stock valued at $118,816,000 after buying an additional 562,249 shares during the last quarter. State Street Corp boosted its stake in Intellia Therapeutics by 17.9% during the third quarter. State Street Corp now owns 5,143,534 shares of the company's stock worth $105,700,000 after buying an additional 780,754 shares during the period. Regeneron Pharmaceuticals Inc. acquired a new stake in shares of Intellia Therapeutics during the fourth quarter valued at about $43,177,000. Finally, Geode Capital Management LLC raised its stake in shares of Intellia Therapeutics by 2.0% in the 4th quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company's stock valued at $27,865,000 after acquiring an additional 45,930 shares during the period. Hedge funds and other institutional investors own 88.77% of the company's stock.
Insider Activity
In related news, CEO John M. Leonard sold 26,807 shares of the company's stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 29,000 shares of company stock valued at $352,551 in the last 90 days. Company insiders own 3.20% of the company's stock.
About Intellia Therapeutics
(
Get Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
See Also
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
